GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Osiris Therapeutics Inc (NAS:OSIR) » Definitions » Price-to-Free-Cash-Flow

Osiris Therapeutics (Osiris Therapeutics) Price-to-Free-Cash-Flow : 93.09 (As of May. 11, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Osiris Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-11), Osiris Therapeutics's share price is $18.99. Osiris Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $0.20. Hence, Osiris Therapeutics's Price-to-Free-Cash-Flow Ratio for today is 93.09.

The historical rank and industry rank for Osiris Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

OSIR's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.585
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Osiris Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2018 was $-0.17. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.20.


Osiris Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Osiris Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Osiris Therapeutics Price-to-Free-Cash-Flow Chart

Osiris Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 66.18

Osiris Therapeutics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 141.91 43.02 66.18

Competitive Comparison of Osiris Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Osiris Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Osiris Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Osiris Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Osiris Therapeutics's Price-to-Free-Cash-Flow falls into.



Osiris Therapeutics Price-to-Free-Cash-Flow Calculation

Osiris Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=18.99/0.204
=93.09

Osiris Therapeutics's Share Price of today is $18.99.
Osiris Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Osiris Therapeutics  (NAS:OSIR) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Osiris Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Osiris Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Osiris Therapeutics (Osiris Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7015 Albert Einstein Drive, Columbia, MD, USA, 21046-1707
Osiris Therapeutics is a biotechnology company involved in researching, developing, and marketing cellular regenerative medicine products. The company's therapeutic areas focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products. Osiris has accomplished commercial success with products in orthopedics, sports medicine, and wound care, such as Cartiform, Ovation, and Grafix.
Executives
Reinhart Charles A. Iii director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Linda L Chang officer: Chief Financial Officer ONE PARK PLACE, STE 450, ANNAPOLIS MD 21401
Shauna L Vernal officer: Chiel Legal Officer
Linda Palczuk officer: President & CEO 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
David L White director
Thomas J Knapp director 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jacoby Philip R Jr officer: Principal Accounting Officer
C Randal Mills director, officer: President & CEO 18366 CALLE STELLINA, RANCHO SANTA FE CA 92091
Jay M Moyes director
Stephen W Potter officer: Senior Vice President 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gregory Hurd Barnhill director

Osiris Therapeutics (Osiris Therapeutics) Headlines

From GuruFocus